Related Experiment Video
Updated: Feb 2, 2026
10:03
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
786
Noise Pollution and Arterial Hypertension
Thomas Münzel1, Mette Sørensen2
1Center for Cardiology, University Medical Center Mainz, Mainz, Germany.
European Cardiology
|November 13, 2018
Summary
Noise pollution impacts cardiovascular health, leading to increased blood pressure and heart rate. This review focuses on non-auditory effects like noise-induced arterial hypertension from environmental and occupational noise exposure.
Area of Science:
- Environmental Health
- Cardiovascular Physiology
- Toxicology
Background:
- Noise exposure is a widespread environmental stressor affecting multiple physiological systems.
- Acute noise exposure can trigger immediate cardiovascular responses, including elevated blood pressure and heart rate.
- Understanding the non-auditory consequences of noise is crucial for public health.
Purpose of the Study:
- To review the impact of noise pollution on the cardiovascular system.
- To highlight the non-auditory effects of noise, specifically noise-induced arterial hypertension.
- To synthesize current knowledge on noise's cardiovascular risks.
Main Methods:
- Literature review of studies on noise exposure and cardiovascular outcomes.
- Analysis of experimental and real-world data on noise's physiological effects.
- Focus on epidemiological and clinical research concerning hypertension.
Main Results:
- Noise exposure is linked to significant increases in blood pressure and heart rate.
- Traffic noise simulation and occupational noise exposure elicit measurable cardiovascular changes.
- Non-auditory effects, such as hypertension, are a key concern.
Conclusions:
- Noise pollution poses a significant threat to cardiovascular health.
- Noise-induced arterial hypertension is a critical non-auditory health outcome.
- Mitigation strategies for noise exposure are essential for preventing cardiovascular disease.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
605
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
605
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
467
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
467
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
509
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
509
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
619
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
619
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
534
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
534
01:28Hypertension I: Introduction
879
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
879